Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in Human, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of the Tolerability, Safety, and Immunogenicity of MVX01, a Pneumococcal Vaccine Candidate, in Healthy Adult Participants

NCT06337643 is registered in ClinicalTrials.gov with Matrivax Research and Development Corporation as lead sponsor.

NCT NCT06337643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06337643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in Human, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of the Tolerability, Safety, and Immunogenicity of MVX01, a Pneumococcal Vaccine Candidate, in Healthy Adult Participants
Lead sponsor
Matrivax Research and Development Corporation
Phase
Phase 1
Overall status
Unknown status
Start date
March 7, 2023
Completion date
April 16, 2024
Enrollment
75 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pneumococcal vaccine